Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

3952 Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow HarvestMain Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
AMGN 1911CC 00164A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related DisordersMain Campus Phase 1Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML)
BIP 191314-307A Phase III Randomised, Double-Blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination with Subcutaneous Low-Dose Cytarabine vs. Placebo + Low-Dose Cytarabine in Patients 65 Years and older with Previously Untreated Acute Myeloid Leukaemia, who are Ineligible for Intensive Remission Induction TherapyMain Campus Phase 3Leukemia, Acute Myeloid (AML)
CASE 491314-147A Single Arm, Phase II study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients with Acute Myeloid Leukemia undergoing Remission Induction therapyMain Campus Phase 2Leukemia, Acute Myeloid (AML)
CASE 791314-492A Phase 1 Study of MLN9708 in Combination with MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)Main Campus Phase 1Leukemia, Acute Myeloid (AML)
CBMT 1911CC00043(Adult/Pediatric) KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor Main Campus  Blood & Marrow Transplant (BMT), Leukemia, Acute Myeloid (AML)
CBMT 191214-139(Pediatric) The Role of Minimal Residual Disease Testing before and after Hematopoietic Cell Transplantation for Pediatric Acute Myeloid LeukemiaMain Campus  Blood & Marrow Transplant (BMT), Leukemia, Acute Myeloid (AML)
CYC 1911CC12-206A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid LeukemiaFlorida Weston, Main Campus Phase 3Leukemia, Acute Myeloid (AML)
FHCRC 191314-207Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study Main Campus Phase 4Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
KALO 1Z1213-595Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic MalignanciesMain Campus Phase 2Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
PFIZ 191213-294PFIZ 1912 – CC13-294: (B1371003) A phase 1b/2 study to evaluate the safety and efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-c or decitabine in patients with AML or high-risk MDSMain Campus Phase 1, Phase 2Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
SEGE 191313-1393A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemiaMain Campus Phase 1Leukemia, Acute Myeloid (AML)
SWOG 0919CC777A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous LeukemiaMain Campus Phase 2Leukemia, Acute Myeloid (AML)
SWOG 120313-415A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)Main Campus Phase 3Leukemia, Acute Myeloid (AML)
SWOG 131213-1292S1312 testing the addition of Inotuzumab Ozogamicin to usual chemotherapy in relapsed and refractory acute leukemiaMain Campus Phase 1Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.